A MedTech engineer turning to defence

Hydrix Limited (ASX:HYD) is an Australian product design and engineering Business that is trying to shift part of its focus from medical device services towards defence technology. That pivot, set out in a series of announcements between May and August 2026, is the central point for anyone following the company, alongside a recapitalisation.

Hydrix is based in Mulgrave, Victoria, has about 54 employees and reports three segments: Hydrix Services, which provides design and development consulting; Hydrix Medical, which distributes the Guardian heart attack warning system and the Implicity remote cardiac monitoring software; and Hydrix Ventures, which invests in early-stage medtech companies.

The defence strategy

On 25 May 2026 the company announced it had established a Defence subsidiary, and an investor presentation on its growth plan followed on 29 May. A letter from the Executive Chairman dated 28 August 2026, said Hydrix Defence aims to acquire, license and develop technologies in areas such as advanced sensing, autonomy, electronic warfare, navigation and counter-UAS, and to move from selling engineering time towards owning technology, which management expects could bring higher-margin, recurring revenue.

That is company intention, not a result, and the letter quantifies no forecasts. Disclosed defence work includes a $1.2 million contract with NIOA Group for a counter-UAS payload subsystem and work with Phasor Innovation on quantum sensing and navigation for GPS-denied environments. Contract values are not recognised revenue until work is performed.

Medical work and the funding pause

The same letter lists FY26 sales contract wins of A$11.7 million, including a $2.5 million SynCardia Systems contract for its next-generation Emperor Total Artificial Heart and a $3.4 million contract with Remedy Robotics for an endovascular robotics platform. It adds that sales since year end were roughly A$4.0 million.

The letter also discloses a setback: fourth-quarter revenue and Cash Flow were affected by a temporary funding-related pause in the SynCardia Emperor programme and by a delayed receivables payment.

Capital raising and dilution

On 18 May 2026 Hydrix announced an accelerated renounceable entitlement offer with a headline target of $8.18 million. The institutional component raised $3.89 million (20 May), with a retail offer and shortfall bookbuild in June. The chairman's letter describes A$5.2 million raised through the offer in the June quarter, so the amount finally raised appears lower than the headline target; the final figure should be confirmed in the company's filings.

The letter also says Loan and convertible note holders agreed to convert a majority of their Debt into equity. The company says this reduces future cash obligations, but converting debt and issuing entitlement shares both dilute holders who did not participate. Cash balance and quarterly burn were not available from the sources reached, and are not stated here.

Financial history and risks

FY26 revenue was A$9.74 million and the net loss A$6.72 million, against revenue of A$10.09 million and a loss of A$3.65 million in FY25. The Annual Report is expected around 20 October 2026, though the date has not been confirmed.

Risks are specific. Defence has long sales cycles and concentrated customers; and medical clients' funding can pause projects, as the SynCardia episode shows. Hydrix has recorded losses in each of the last five years.